<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533613498215</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533613498215</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Product Shortage Considerations</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Parenteral Nutrition Amino Acids Product Shortage Considerations</article-title>
</title-group>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>4</issue>
<fpage>524</fpage>
<lpage>527</lpage>
<permissions>
<copyright-statement>© 2013 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>During the amino acids shortage period, consider one or more of the following measures:</p>
<list id="list1-0884533613498215" list-type="order">
<list-item><p>Assess each patient as to the indication for PN and provide nutrition via the oral or enteral route when possible.</p></list-item>
<list-item><p>Purchase only as much amino acid products supply as needed. In the interest of fair allocation to all patients nationally, please do not stockpile.</p></list-item>
<list-item><p>Use neonatal/pediatric-specific amino acids (or specialty amino acids) ONLY for their indicated patient populations.</p></list-item>
<list-item><p>Use high-concentration amino acid products (eg, &gt;10%) sparingly. For example, save high-concentration amino acids for fluid-restricted patients requiring PN.</p></list-item>
<list-item><p>Compound PN in a single, central location (either in a centralized pharmacy or as outsourced preparation) to decrease inventory waste. Consider a supply outreach to other facilities in your geographic location.</p></list-item>
<list-item><p>Consider reviewing the entire portfolio of amino acid products available nationally. There may be a shortage in one concentration but availability in another. See <xref ref-type="table" rid="table1-0884533613498215">Table 1</xref> for a detailed listing.</p></list-item>
<list-item><p>Different brands of amino acid products are not always directly substitutable, especially for total nutrient admixture (3-in-1) vs dextrose/amino acids (2-in-1) PN formulations. They may have different pHs, different calcium-phosphorus solubilities, different amounts of phosphorus, and other characteristics that should be considered.</p></list-item>
<list-item><p>Assess your PN patient population to determine if a standardized, commercial PN product<sup><xref ref-type="bibr" rid="bibr1-0884533613498215">1</xref></sup> (“premix” PN) may be appropriate for a portion of your patient population.</p></list-item>
<list-item><p>Facilities and practitioners must continue to observe and be compliant with the product labeling (eg, package insert), USP General Chapter &lt;797&gt; Pharmaceutical Compounding–Sterile Preparations, and state boards of pharmacy rules and regulations.</p></list-item>
<list-item><p>Report severe drug product shortage information to the FDA Drug Shortage Program (<ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm142398.htm">http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm142398.htm</ext-link>).</p></list-item>
<list-item><p>Report any patient problems related to shortages to ISMP Medication Errors Reporting Program. To access that reporting mechanism, click here.</p></list-item>
</list>
<table-wrap id="table1-0884533613498215" position="float">
<label>Table 1.</label>
<caption>
<p>Intravenous Amino Acid Products in the United States.</p>
</caption>
<graphic alternate-form-of="table1-0884533613498215" xlink:href="10.1177_0884533613498215-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left"><bold>Company</bold></th>
<th align="center"><bold>Product</bold></th>
<th align="center"><bold>Sulfite-Free?</bold></th>
<th align="center"><bold>Size</bold></th>
<th align="center"><bold>NDC</bold></th>
<th align="center"><bold>Shortage Reason (per New Legislation–FDASIA)</bold></th>
<th align="center"><bold>Shortage Reason (per ASHP)</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Hospira, Inc (customer service: 1-877-946-7747)</bold></td>
<td/>
<td/>
<td/>
<td/>
<td>Other; requirements related to complying with good manufacturing practices and discontinuation of the manufacture of the drug</td>
<td>Hospira suspended manufacturing all Aminosyn presentations in September 2012 for quality improvement.</td>
</tr>
<tr>
<td/>
<td><bold>Aminosyn II 10%</bold></td>
<td>Sulfite free</td>
<td>1-L bag</td>
<td>0409-4164-05</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn 10%</bold></td>
<td>Sulfite free</td>
<td>500-mL bag</td>
<td>0409-4191-03</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn 8.5%</bold></td>
<td>Sulfite free</td>
<td>500-mL bag</td>
<td>0409-4187-03</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn II 15%</bold></td>
<td>Sulfite free</td>
<td>2-L bag</td>
<td>0409-7171-17</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn II 10%</bold></td>
<td>Sulfite free</td>
<td>2-L bag</td>
<td>0409-7172-17</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn 10%</bold></td>
<td>Sulfite free</td>
<td>1 L</td>
<td>0409-4191-05</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn II 10%</bold></td>
<td>Sulfite free</td>
<td>500 mL</td>
<td>0409-4164-03</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn HBC 7%</bold></td>
<td>Sulfite free</td>
<td>500 mL</td>
<td>0409-4168-03</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn 3.5%</bold></td>
<td>Sulfite free</td>
<td>1 L</td>
<td>0409-4196-05</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn II 8.5%</bold></td>
<td>Sulfite free</td>
<td>500 mL</td>
<td>0409-4162-03</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn II 8.5% with electrolytes</bold></td>
<td>Sulfite free</td>
<td>500 mL</td>
<td>0409-4171-03</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn 8.5% with electrolytes</bold></td>
<td>Sulfite free</td>
<td>500 mL</td>
<td>0409-4203-03</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn-PF 7% (specialty amino acids)</bold></td>
<td>Sulfite free</td>
<td>500 mL</td>
<td>0409-4178-03</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn-PF 10% (specialty amino acids)</bold></td>
<td>Sulfite free</td>
<td>1000 mL</td>
<td>0409-4179-05</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn RF 5.2% (specialty amino acids)</bold></td>
<td>Sulfite free</td>
<td>500 mL</td>
<td>0409-4166-03</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Aminosyn II 10%</bold></td>
<td/>
<td>2-L bag</td>
<td>0409-7121-07</td>
<td/>
<td/>
</tr>
<tr>
<td><bold>B. Braun Medical, Inc (customer service: 1-800-227-2862)</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>BBraun discontinued several FreAmine presentations in October 2011. BBraun received FDA approval for an amino acid 15% solution that released in early June 2012.</td>
</tr>
<tr>
<td/>
<td><bold>TrophAmine 6% (specialty amino acids)</bold></td>
<td/>
<td>500 mL</td>
<td>00264-9361-55</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>TrophAmine 10% (specialty amino acids)</bold></td>
<td/>
<td>500 mL</td>
<td>00264-9361-55</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>FreAmine III 3%</bold></td>
<td/>
<td>1000 mL</td>
<td>00264-9040-55</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>FreAmine III 8.5%</bold></td>
<td/>
<td>1000 mL</td>
<td>00264-9030-55</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>FreAmine III 10%</bold></td>
<td/>
<td>1000 mL</td>
<td>00264-9010-55</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>FreAmine HBC 6.9% (specialty amino acids)</bold></td>
<td/>
<td>750 mL</td>
<td>00264-9350-55</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>NephrAmine 5.4% (specialty amino acids)</bold></td>
<td/>
<td>250 mL</td>
<td>00264-1909-55</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>HepatAmine 8% (specialty amino acids)</bold></td>
<td/>
<td>500 mL</td>
<td>00264-9371-55</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>15% Amino Acids</bold></td>
<td/>
<td>1000 mL</td>
<td>00264-3200-55</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>ProcalAmine (3% Specialty amino acids and 3% glycerin injection with electrolytes)</bold></td>
<td/>
<td>1000 mL</td>
<td>00264-1915</td>
<td/>
<td/>
</tr>
<tr>
<td><bold>Baxter (customer service: 1-800-262-3784)</bold></td>
<td/>
<td/>
<td/>
<td/>
<td>Demand increase for the drug. Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through December 2012. Clinimix is a viable source of amino acids for most patients requiring parenteral nutrition.</td>
<td>Baxter is allocating many amino acid solutions in response to current market conditions. Clinimix or Clinimix E products are not affected.</td>
</tr>
<tr>
<td/>
<td><bold>Travasol 10%</bold></td>
<td/>
<td>500 mL</td>
<td>00338-0644-03</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Travasol 10%</bold></td>
<td/>
<td>1000 mL</td>
<td>00338-0644-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Travasol 10%</bold></td>
<td/>
<td>2000 mL</td>
<td>00338-0644-06</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Prosol 20%</bold></td>
<td>Sulfite free</td>
<td>2000 mL</td>
<td>00338-0499-06</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Clinisol 15%</bold></td>
<td>Sulfite free</td>
<td>500 mL</td>
<td>00338-0502-03</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Clinisol 15%</bold></td>
<td>Sulfite free</td>
<td>2000 mL</td>
<td>00338-0502-06</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Premasol 6% (specialty amino acids)</bold></td>
<td>Sulfite free</td>
<td>500 mL</td>
<td>00338-1131-03</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Premasol 10% (specialty amino acids)</bold></td>
<td>Sulfite free</td>
<td>500 mL</td>
<td>00338-1130-03</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Premasol 10% (specialty amino acids)</bold></td>
<td>Sulfite free</td>
<td>1000 mL</td>
<td>00338-1130-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Premasol 10% (specialty amino acids)</bold></td>
<td>Sulfite free</td>
<td>2000 mL</td>
<td>00338-1130-06</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>Hepatosol 8% (specialty amino acids)</bold></td>
<td>Sulfite free</td>
<td>500 mL</td>
<td>00338-0504-03</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX 2.75/5 (2.75% amino acid in 5% dextrose)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1132-03/0338-1083-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX 4.25/5 (4.25% amino acid in 5% dextrose)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/ 2000 mL</td>
<td>0338-1133-03/0338-1089-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX 4.25/10 (4.25% amino acid in 10% dextrose)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1134-03/0338-1091-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX 4.25/20 (4.25% amino acid in 20% dextrose)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1135-03/0338-1093-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX4.25/25 (4.25% amino acid in 25% dextrose)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1136-03/0338-1095-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX 5/15 (5.0% amino acid in 15% dextrose)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1137-03/0338-1099-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX 5/20 (5.0% amino acid in 20% dextrose)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1138-03/0338-1101-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX 5/20 (5.0% amino acid in 25% dextrose)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1139-03/0338-1103-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX E 2.75/5 (2.75% amino acid with electrolytes in 5% dextrose with calcium)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1142-03/0338-1107-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX E 2.75/10 (2.75% amino acid with electrolytes in 10% dextrose with calcium)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1143-03/0338-1109-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX E4.25/5 (4.25% amino acid with electrolytes in 5% dextrose with calcium)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1144-03/0338-1113-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX E 4.25/10 (4.25% amino acid with electrolytes in 10% dextrose with calcium)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1145-03/0338-1115-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX E 4.25/25 (4.25% amino acid with electrolytes in 25% dextrose with calcium)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1146-03/0338-1119-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX E 5/15 (5.0% amino acid with electrolytes in 15% dextrose with calcium)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1147-03/0338-1123-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX E 5/20 (5.0% amino acid with electrolytes in 20% dextrose with calcium)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1148-03/0338-1125-04</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td><bold>CLINIMIX E 5/25 (5.0% amino acid with electrolytes in 25% dextrose with calcium)</bold></td>
<td>Sulfite free</td>
<td>1000 mL/2000 mL</td>
<td>0338-1149-03/0338-1127-04</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0884533613498215">
<p>ASHP, American Society of Health-System Pharmacists; FDA, Food and Drug Administration; FDASIA, ; NDC, .Up-to-date information on drug shortages may be found at U.S. FDA, <italic>Current Drug Shortages A–D. Drug Safety and Availability: Drug Shortages</italic> (<ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm">http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm</ext-link>), and American Society of Health-System Pharmacists, <italic>Amino Acid Products: Current Shortages</italic> (<ext-link ext-link-type="uri" xlink:href="http://www.ashp.org/DrugShortages/Current/bulletin.aspx?id=671">http://www.ashp.org/DrugShortages/Current/bulletin.aspx?id=671</ext-link>).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>For the most up-to-date supply information, please see these websites:<list id="list2-0884533613498215" list-type="simple">
<list-item><p>American Society of Health-System Pharmacists (ASHP), Drug Shortages Resource Center (<ext-link ext-link-type="uri" xlink:href="http://www.ashp.org/shortages?WT.ac=hp%5FPopLinks%5FDrug%5FShortages">http://www.ashp.org/shortages?WT.ac=hp%5FPopLinks%5FDrug%5FShortages</ext-link>)</p></list-item>
<list-item><p>U.S. Food and Drug Administration, Drug Shortage Program, Current Drug Shortages (<ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050792.htm">http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050792.htm</ext-link>)</p></list-item>
<list-item><p>A.S.P.E.N. News section (<ext-link ext-link-type="uri" xlink:href="http://www.nutritioncare.org/">http://www.nutritioncare.org/</ext-link>)</p></list-item>
</list></p>
</body>
<back>
<fn-group>
<fn fn-type="other">
<label>Important Note:</label>
<p>These recommendations do not constitute medical or professional advice, and should not be taken as such. To the extent the information published herein may be used to assist in the care of patients, this is the result of the sole professional judgment of the attending health professional whose judgment is the primary component of quality medical care.</p>
<p>Developed by the A.S.P.E.N. Intravenous Amino Acids National Shortage Task Force: Vincent W. Vanek, MD, FACS, CNSP (Chair); Jay Mirtallo, MS, RPh, BCNSP, FASHP; Larry Robinson, PharmD; Marty Kochevar, MS, RPh, BCNSP; and Peggi Guenter, PhD, RN, CNSN. (2010)</p>
<p>Revised by the A.S.P.E.N. CPC Shortage Subcommittee: Steve Plogsted, PharmD, BCNSP, CNSC (Chair); Gary Brooks, PharmD, BCPS, BCNSP; John DiBaise, MD; Antoinette Neal, RN, CRNI, CNSC, VA-BC; and Joseph Ybarra, Pharm D, BCNSP. Approved by the Clinical Practice Committee and the A.S.P.E.N. Board of Directors.</p>
</fn>
</fn-group>
<ref-list>
<title>Reference</title>
<ref id="bibr1-0884533613498215">
<label>1.</label>
<citation citation-type="journal">
<collab>A.S.P.E.N. Board of Directors and Task Force on Parenteral Nutrition Standardization</collab>; <person-group person-group-type="author">
<name><surname>Kochevar</surname><given-names>M</given-names></name>
<name><surname>Guenter</surname><given-names>P</given-names></name>
<name><surname>Holcombe</surname><given-names>B</given-names></name>
<name><surname>Malone</surname><given-names>A</given-names></name>
<name><surname>Mirtallo</surname><given-names>J. A.S.P.E.N.</given-names></name>
</person-group> <article-title>statement on parenteral nutrition standardization</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2007</year>;<volume>31</volume>(<issue>5</issue>):<fpage>441</fpage>-<lpage>448</lpage>.</citation>
</ref>
</ref-list>
<ref-list>
<title>Suggested Reading</title>
<ref id="bibr2-0884533613498215">
<label>1.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Mirtallo</surname><given-names>JM</given-names></name>
</person-group>. <article-title>The drug shortage crisis</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2011</year>;<volume>35</volume>:<fpage>433</fpage>. <ext-link ext-link-type="uri" xlink:href="http://pen.sagepub.com/content/35/4/433.full.pdf+html">http://pen.sagepub.com/content/35/4/433.full.pdf+html</ext-link></citation>
</ref>
<ref id="bibr3-0884533613498215">
<label>2.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Mirtallo</surname><given-names>JM</given-names></name>
<name><surname>Holcombe</surname><given-names>B</given-names></name>
<name><surname>Kochevar</surname><given-names>M</given-names></name>
<name><surname>Guenter</surname><given-names>P</given-names></name>
</person-group>. <article-title>Parenteral nutrition product shortages: The A.S.P.E.N. strategy</article-title>. <source>Nutr Clin Pract</source>. <year>2012</year>; <volume>27</volume>:<fpage>385</fpage>-<lpage>391</lpage>. <ext-link ext-link-type="uri" xlink:href="http://ncp.sagepub.com/content/27/3/385.full.pdf+html">http://ncp.sagepub.com/content/27/3/385.full.pdf+html</ext-link></citation>
</ref>
<ref id="bibr4-0884533613498215">
<label>3.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Holcombe</surname><given-names>B</given-names></name>
</person-group>. <article-title>Parenteral nutrition product shortages: impact on safety</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2012</year>;<volume>36</volume>:<fpage>44S</fpage>-<lpage>47S</lpage>. <ext-link ext-link-type="uri" xlink:href="http://pen.sagepub.com/content/36/2_suppl/44S.full.pdf+html">http://pen.sagepub.com/content/36/2_suppl/44S.full.pdf+html</ext-link></citation>
</ref>
<ref id="bibr5-0884533613498215">
<label>4.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>MR</given-names></name>
<name><surname>Smetzer</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Weathering the storm: managing the drug shortage crisis</article-title>. <source>Hosp Pharm</source>. <year>2011</year>:<volume>46</volume>:<fpage>7</fpage>-<lpage>11</lpage>. <ext-link ext-link-type="uri" xlink:href="http://www.metapress.com.libproxy.lib.unc.edu/content/c03646k108617r12/fulltext.pdf">http://www.metapress.com.libproxy.lib.unc.edu/content/c03646k108617r12/fulltext.pdf</ext-link></citation>
</ref>
</ref-list>
</back>
</article>